Skip to content
DataLookout
Menu

NCT03952598

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 249 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial status changed: Suspended → Completed
    • Primary and study completion dates changed from estimate of Dec 31, 2027 to Oct 28, 2026
  2. New version filed on ClinicalTrials.gov
  3. Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027v224
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Study on hold pending possible updates with the team.
    • Enrollment target: estimated 270 to confirmed 42
    v221
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To monitor the quantitative levels of 2-hydroxyglutarate (2-HG) longitudinally in patients with IDH mutant gliomas via proton magnetic resonance spectroscopy (1H-MRS)
Timeframe: 5 years

Secondary (1)

Determine the utility of 2-HG detection by 1H-MRS to predict higher-grade transformation (HT) and hypermutator phenotype (HMP) by correlating the 2-HG level with pathological diagnosis and tumor mutational load of the tumor tissue at time of rec...

Arms and interventions

1/Arm 1Experimental

Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) -- THIS ARM IS NOW CLOSED

2/Arm 2Experimental

Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS) and HP 13C pyruvate MRSI

3/Arms 3Experimental

Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS)

Drugs: HP 13C Pyruvate

Devices: 3T MRI scanner

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States